BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer
Rhea-AI Summary
BriaCell (Nasdaq:BCTX) reported that an independent Data Safety Monitoring Board issued a sixth consecutive positive recommendation for its pivotal Phase 3 Bria-ABC study of Bria-IMT plus checkpoint inhibitor in metastatic breast cancer.
The DSMB found no safety concerns and advised continuing the Fast Track-designated trial without modifications.
AI-generated analysis. Not financial advice.
Positive
- Sixth consecutive positive DSMB recommendation for Phase 3 Bria-ABC study
- DSMB identified no safety concerns and advised continuation without modifications
- Quarterly DSMB oversight supports ongoing safety monitoring of Bria-IMT plus CPI
- Phase 3 metastatic breast cancer study conducted under FDA Fast Track designation
Negative
- None.
News Market Reaction – BCTX
On the day this news was published, BCTX declined 2.01%, reflecting a moderate negative market reaction. Argus tracked a trough of -11.1% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $543K from the company's valuation, bringing the market cap to $26.46M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
BCTX was down 6.18% pre-news while peers were mixed: ADAP (-17.57%), NXTC (-24.13%), CYCC (-5.84%), PRTG (-10.39%), and IMNN (+2.8% overall, +13.18% on the momentum scan). Moves do not show a clear, uniform sector direction.
Previous Clinical trial Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 22 | ASCO 2026 data | Positive | -6.2% | Positive Phase 2 survival and biomarker data for Bria‑IMT in metastatic breast cancer. |
| May 13 | Site expansion | Positive | +2.5% | Added Penn Medicine’s Abramson Cancer Center as a Phase 3 Bria‑ABC study site. |
| May 12 | Enrollment update | Positive | -1.9% | Reported Phase 3 Bria‑ABC enrollment surpassing 230 patients with 315+ screened. |
| May 07 | Site expansion | Positive | -1.2% | Added NYU Langone’s Perlmutter Cancer Center as a clinical site for the Phase 3 study. |
| Apr 27 | ASCO presentations | Positive | +3.9% | Announced six metastatic breast cancer clinical data presentations for ASCO 2026. |
Recent clinical trial headlines have generally been positive while share reactions have been mixed, with several negative moves following favorable updates.
Over the past month, BriaCell has repeatedly highlighted progress in its Bria‑IMT™ metastatic breast cancer program under FDA Fast Track. Clinical‑trial news on Apr 27, May 7, May 12, May 13, and May 22 covered expanding trial sites, strong Phase 2 survival data, and multiple ASCO 2026 presentations. Price reactions have alternated between modest gains and declines, indicating inconsistent trading responses to similar clinical milestones.
Historical Comparison
Past clinical‑trial updates (5 events) produced an average move of -0.6%, with mixed up and down reactions despite consistently constructive trial progress.
Tag‑matched history shows steady advancement of the Bria‑IMT Phase 3 program: expanding major cancer center sites, surpassing enrollment milestones, repeated positive DSMB reviews, and increasing ASCO visibility, all under FDA Fast Track designation.
Market Pulse Summary
This announcement reports a sixth consecutive positive DSMB recommendation with no safety concerns for BriaCell’s pivotal Phase 3 Bria‑ABC study under FDA Fast Track. It reinforces the tolerability of Bria‑IMT plus checkpoint inhibitor in metastatic breast cancer. In context of recent ASCO data and expanding trial sites, key watchpoints remain future efficacy readouts, enrollment progression, and how ongoing development is balanced against the company’s funding needs.
Key Terms
data safety monitoring board medical
immunotherapy medical
immune checkpoint inhibitor medical
fast track designation regulatory
AI-generated analysis. Not financial advice.
- Independent DSMB has identified no safety concerns, to date, and recommends continuation of BriaCell’s pivotal Phase 3 study of Bria-IMT™ plus immune check point inhibitor
- Sixth consecutive positive DSMB recommendation to proceed highlights the favorable safety and tolerability of BriaCell’s novel immunotherapy approach
- Phase 3 study is being conducted under FDA Fast Track Designation, reflecting the significant unmet need in metastatic breast cancer
PHILADELPHIA and VANCOUVER, British Columbia, May 26, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that the independent Data Safety Monitoring Board (DSMB) has issued its sixth consecutive positive recommendation following review of safety data from BriaCell’s pivotal Phase 3 Bria-ABC study of Bria-IMT plus immune checkpoint inhibitor (CPI) in patients with metastatic breast cancer (NCT06072612).
Following its review, the DSMB raised no safety concerns and recommended that the study continue without modifications. DSMB meetings occur quarterly in accordance with the study protocol. BriaCell’s ongoing pivotal Phase 3 study is being conducted under Fast Track designation granted by the US Food and Drug Administration (FDA), reflecting the significant unmet medical need in metastatic breast cancer.
“We are highly encouraged by the sixth consecutive positive recommendation of the DSMB for continuation of BriaCell’s pivotal Phase 3 Bria-ABC study,” said Dr. William V. Williams, President and Chief Executive Officer of BriaCell. “This important milestone represents another step forward in advancing BriaCell’s novel immunotherapy approaches for patients with urgent unmet medical needs.”
About BriaCell Therapeutics Corp.
BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/.
Safe Harbor
This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about Bria-IMT’s safety and tolerability profile, as related to the positive DSMB recommendations; the continued conduct and advancement of BriaCell’s pivotal Phase 3 Bria‑ABC study under FDA Fast Track designation; and Bria-IMT’s potential as a transformative immunotherapy for patients with metastatic breast cancer, are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements, such as those are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading “Risks and Uncertainties” in the Company’s most recent Management’s Discussion and Analysis, under the heading “Risk Factors” in the Company’s most recent Annual Information Form, and under “Risks and Uncertainties” in the Company’s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company’s profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.
Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact Information
Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com
Investor Relations Contact:
investors@briacell.com
